btw, NNLX transition to the virus field may be another logical explanation for Michelle's departure,since:

''NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible''

i havent seen this connection mentioned before